Abstract:Radiation therapy prior to surgery has increasingly become the standard of care for locally advanced prostate cancer, however tumor radioresistance remains a major clinical problem. While restoration of microRNA-145 (miR-145) expression reduces chemoradioresistance in glioblastoma and suppress prostate cancer proliferation, migration and invasion, the role of miR-145 in response to radiation therapy for prostate cancer is still unknown. The aim of this study was to investigate the role of miR-145 in determining the tumor response to radiation treatment in prostate cancer. Human prostate cancer cells LNCAP and PC3 were transfected with miR-145 mimic. Clonogenic assay was used to determine whether overexpression of miR-145 could alter radiation response in vitro. Immunofluorescence of γ-H2AX and flow cytometric analysis of phosphorylated histone H3 were performed to investigate the potential mechanisms contributing to the enhanced radiation-induced cell killing induced by miR-145. In addition, a qPCR-based array was used to detect the possible miR-145-mediated regulated genes involved. Tumor growth delay assays and survival curves were then analyzed in an animal model to investigate whether miR-145 induced radiosensitivity in vivo. Furthermore, miR-145 expression was assessed in 30 prostate tumor tissue biopsies taken prior to neoadjuvant radiotherapy using miRNA arrays. Our current study suggested that ectopic expression of miR-145 significantly sensitized prostate cancer cells to radiation and we used γ-H2AX phosphorylation as a surrogate marker of radiotherapy response versus miR-145 expression levels. We observed significantly more foci per cell in the group treated with miR-145 and radiation. In addition, mitotic catastrophe was significantly increased in cells receiving miR-145 and radiation. The above results suggest that miR-145 appears to reduced the efficiency of the repair of radiation-induced DNA double-strand breaks in cells. A detailed examination of the involvement of the DNA repair pathway showed that miR-145 reduced the expression of 10 genes involved in DNA repair according to a qPCR-based array data. Irradiation of subcutaneous PC3 tumors in mice treated with R11-miR-145 (a cellular permeable peptide, previously reported) resulted in an increase in radiation-induced tumor growth delay and lived the longest after combination treatment. Moreover, miR-145 expression was significantly increased in patients demonstrating good response (PSA < 2.0 ng/ml/year) to neoadjuvant radiotherapy, while expression of the miR-145-regulated DNA repair genes was significantly decreased. In conclusion, these data suggest a possible mechanism for miR-145 radiosensitivity, potentially through down regulating of DNA repair. This novel study shows a role for miR-145 in modulating radiosensitivity in vivo and highlights the need for further study investigating the potential role of miR-145 as both a predictive marker of response and a novel therapeutic agent with which to enhance the efficacy of radiation therapy.

miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA

Targeting MicroRNAs in Prostate Cancer Radiotherapy

MicroRNA-145 Modulates Tumor Sensitivity to Radiation in Prostate Cancer

Mir-144-5p Enhances The Radiosensitivity Of Non-Small-Cell Lung Cancer Cells Via Targeting Atf2

Mir-30A Radiosensitizes Non-Small Cell Lung Cancer by Targeting ATF1 That is Involved in the Phosphorylation of ATM.

Microrna-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor Tfpi-2

Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling Through Critical Pathways to Regulate Cell Viability in Prostate Cancer

Loss of miR-200c-3p promotes resistance to radiation therapy via the DNA repair pathway in prostate cancer

Radiosensitizing Effects of Mir‐18a‐5p on Lung Cancer Stem‐like Cells Via Downregulating Both ATM and HIF‐1α

Abstract 471: Attenuation of circulating miR-17-5p, miR-20b-5p, and miR-106a-5p in low-risk prostate cancer patients following proton therapy

LITAF Enhances Radiosensitivity of Human Glioma Cells via the FoxO1 Pathway

Identification of Micror-106B As a Prognostic Biomarker of P53-Like Bladder Cancers by ActMiR

Aberrant Mir-1246 Expression Promotes Radioresistance in Non-Small Cell Lung Cancer: a Potential Prognostic Biomarker and Radiotherapy Sensitization Target.

Abstract A077: MicroRNA drivers of resistance to androgen deprivation therapy in prostate cancer

MiR-99a Enhances the Radiation Sensitivity of Non-Small Cell Lung Cancer by Targeting mTOR

Long noncoding RNA MIAT regulates TP53 ubiquitination and expedites prostate adenocarcinoma progression by recruiting TBL1X

Long Noncoding RNA FAM201A Mediates the Radiosensitivity of Esophageal Squamous Cell Cancer by Regulating ATM and mTOR Expression via miR-101.

Abstract A030: Deciphering the micro-RNA landscape of AKT isoforms and its clinical impact in patients with lung adenocarcinoma

Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.